RxDoctor Payments Data

Michael Marchiano, MD

Internal Medicine · Hayward, CANPI 1275636276

Payments from drug & device makers

$1,966in general payments, 2019–2025

Across 100 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$679
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$233
  • AstraZeneca$164
  • Bayer$158
  • Exact Sciences$148
  • AbbVie$116
  • plus $468 from 10 others

What the payments were for

  • Food & beverage$1,966100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,966 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$73,014
Medicare patients
130
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate36$40,140
EliquisApixaban17$25,424
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,344
Sumatriptan Succinate22$7,204
Levothyroxine Sodium176$3,259
Colchicine19$2,038
Atorvastatin Calcium199$1,986
Metoprolol Succinate118$1,796
Gabapentin88$1,619
Albuterol Sulfate HfaAlbuterol Sulfate46$1,325
Tamsulosin Hcl68$1,008
Amlodipine Besylate198$987
Lisinopril130$934
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen40$886
FenofibrateFenofibrate Nanocrystallized19$866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$25,42417 claims
AbbVieSynthroid$116$44012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Hayward

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →